Drug slated for PBS delisting gets more time

Despite failing to get a higher price for 3.6mg Zoladex, AstraZeneca has announced it will remain subsidised on the PBS for a further six months, and the previously announced continuity program will not proceed.

To see the whole article please log in.

James Quintana Pearce

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here